Skip to content
DataLookout
Menu

NCT07838155

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease

StatusNot Yet Recruiting
PhasePhase 4
Primary completion (estimated)

At risk: Primary completion moved at least 32 days later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Primary and study completion pushed from Jul 2030 to Sep 2030
    • Trial sites expanded: 9 → 12 locations
    • Start date pushed from Oct 2026 to Nov 2026
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Number of Participants with Any Occurrence of Amyloid-Related Imaging Abnormalities (ARIA)
Timeframe: Baseline Up to Week 24, 52
Frequency and Severity of Infusion-Related Reactions
Timeframe: Through Week 52

Secondary (2)

Change from Baseline in Mini Mental State Examination (MMSE) Score
Change from Baseline in Plasma Phosphorylated Tau217 (P-tau217)

Arms and interventions

DonanemabExperimental

Donanemab administered intravenously (IV)

Drugs: Donanemab

Sites

12 sites in 1 country